MRNA Moderna, Inc.

Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

$331.10  +57.71 (21.11%)
As of 11/26/2021 13:43:28 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—General
Index country:  USA
Country of incorporation:  USA
IPO date:  12/07/1993
Outstanding shares:  405,449,527
Average volume:  13,409,971
Market cap:   $110,845,846,187
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    60770K107
ISIN:        US60770K1079
Sedol:      BGSXTS3
Valuation   (See tab for details)
PE ratio:   18.93
PB ratio:   13.19
PS ratio:   9.37
Return on equity:   69.75%
Net income %:   59.69%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy